Investors in GeneDx Holdings Corp. Pursue Recovery Through Class Action Lawsuit

On June 24, 2026, Levi & Korsinsky, LLP announced a class action lawsuit on behalf of investors who purchased shares of GeneDx Holdings Corp. (NASDAQ: WGS) during a turbulent period from April 16, 2025, to May 4, 2026. The lawsuit arises in the wake of a catastrophic 49% drop in stock price following the company’s recent disclosures regarding its performance and acquisitions, particularly the controversial Fabric Genomics acquisition.

The Financial Freefall

Initially, GeneDx's stock had reached a peak of $167.52, buoyed by optimistic market sentiment regarding its growth and acquisitions. However, following disappointing Q1 earnings results revealed on May 4, 2026, the company faced an abrupt stock collapse. Following the after-hours disclosure, shares plummeted from $67.93 to $34.51, marking an unprecedented loss of $33.42 per share. This drastic decline erased billions from shareholder value and raised significant concerns over the accuracy of prior financial statements.

The class action suit centers around allegations that GeneDx misled investors by presenting inflated stock prices without adequately disclosing material issues related to its operations and acquisitions. Specifically, the firm revealed a $31.2 million impairment loss related to Fabric Genomics and slashed its revenue forecasts by approximately $65 million. This represented a substantial blow to investor confidence, as expectations set during the acquisition were left unfulfilled.

Allegations of Misleading Information

The complaint suggests that GeneDx's management misrepresented its market position, leading to an artificial inflation of stock prices during the class period. The firm had touted the potential benefits of the Fabric Genomics acquisition, which, according to recent admissions, may only be viable for international markets, contrary to previous broad applications.

Shareholders who invested in the company during this high point now face nearly an 80% loss in their investments, raising serious questions about the disclosure practices and internal knowledge at GeneDx prior to the release of critical financial data.

What Investors Should Do

Investors who acquired shares during the specified class period are encouraged to assess whether they qualify for recovery. Levi & Korsinsky has initiated efforts to recover losses for affected shareholders, asserting that the significant stock decline necessitates accountability for serious lapses in transparency. The firm is reaching out to those who may be eligible to file for claims, and potential plaintiffs are urged to gather brokerage records that document their purchase dates and share quantities.

Inquiries are already being handled by Joseph E. Levi, Esq. at (212) 363-7500, who assures that participants do not have to face court appearances and that they will not incur upfront legal fees—as securities class actions typically operate on a contingency basis. This means attorneys’ fees are only collected if recovery is achieved.

Conclusion and Next Steps

As the class action suit progresses, GeneDx may face intensifying scrutiny from both investors and regulators. The outcome of the lawsuit could play a significant role in determining the future trajectory of the company and its commitment to transparent practices. For shareholders who experienced losses due to the company's alleged misleading actions, this class action suit represents a vital opportunity for potential recovery. Interested parties should consider contacting Levi & Korsinsky before the deadline of August 3, 2026, to ensure eligibility for participation in this legal action.

In conclusion, the tumultuous situation surrounding GeneDx Holdings Corp. highlights the ongoing need for corporate accountability and transparency in financial disclosures. Investors must remain vigilant and pro-active in seeking redress for misleading practices that have significant financial implications.